BN Business News
Add your company to Business Communicator →

Business · 14/01/2015Updated: 10/17/2026 · 1 min read

FDA Announces Opportunity for Hearing on Proposal to Revoke CHEMBIOMED's U.S. License for Anti-A and Anti-B Monoclonal Antibodies

The FDA is seeking public input on a proposal to revoke CHEMBIOMED's U.S. license for manufacturing Anti-A and Anti-B monoclonal antibodies, citing the company's discontinuation of operations and licensed product manufacturing

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →